Clinical Trial Update: Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy [Phase 3]

View source ↗

Summary

Phase 3 study of subcutaneous immunoglobulin for IgG replacement in patients with primary immunodeficiencies has completed. Results were posted in 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autosomal Recessive Agammaglobulinemia
• Common Variable Immunodeficiency
• X-linked Agammaglobulinemia

Drugs mentioned

• Hizentra (subcutaneous immunoglobulin (IgG))

Snippet

Sponsor: CSL Behring | Conditions: Common Variable Immunodeficiency, X-linked Agammaglobulinemia | Phase 3 | Status: COMPLETED | Results posted: 2011-03-15